Triple-negative breast cancer (TNBC), characterized by the absence of detectable estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)/neu gene overexpression, accounts for 15–20% of all BC cases and predominantly affects younger patients, typically under 40 years old [2]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.